ArticleBMC oral health2026
Development and validation of a nomogram for predicting recurrence risk in pediatric ameloblastoma treated with conservative surgery.
Article in BMC oral health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundAmeloblastoma (AM) constitutes a locally invasive, non-malignant odontogenic neoplasm with significant recurrence potential. In pediatric patients, treatment must balance effective tumor control with the preservation of normal jaw development, leading to a common preference for conservative surgical approaches such as marsupialization or local curettage. However, even with conservative treatment, a subset of children remains at a heightened risk of recurrence. Currently, there is a lack of dedicated clinical tools for predicting recurrence risk within pediatric patients.
methodsIn this retrospective study, 115 pediatric patients with AM who underwent conservative surgical treatment at the Hospital of Stomatology, Sun Yat-sen University between November 2005 and August 2025 were enrolled. Researchers gathered information from clinical examinations, radiographic images, and pathological findings. To pinpoint the key elements contributing to recurrence, both single-variable and multi-variable logistic regression analyses were carried out. Building on these significant predictors, a nomogram forecasting model was then developed. The model’s performance was evaluated by the area under the receiver operating characteristic curve (AUC), the Hosmer–Lemeshow goodness-of-fit test, calibration curve, and decision curve analysis (DCA).
resultsRecurrence occurred in 39 of the 115 patients (33.9%). Multivariate analysis identified female gender (OR = 0.325, P = 0.034) and the surgical approach of curettage and fenestration decompression (CFD) (OR = 0.231, P = 0.021) as protective factors against recurrence. In contrast, a honeycomb radiographic pattern (OR = 16.980, P = 0.018) and involvement of the inferior alveolar nerve (OR = 3.680, P = 0.036) proved to be a major red flag for recurrence. When we put these pieces together in a nomogram, the predictive power was quite impressive, with an AUC of 0.818 (95% CI: 0.734–0.902). The calibration curve indicated excellent agreement between ideal and observed outcomes.
conclusionsThis research marks the creation and verification of the inaugural predictive nomogram designed to estimate the likelihood of recurrence in pediatric ameloblastoma cases managed through conservative surgical approaches. The model exhibits good discriminative ability and calibration, potentially serving as a practical tool to assist clinicians in optimizing surgical planning and tailoring treatment strategies, thereby improving long-term outcomes for affected children.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.